REGENXBIO Inc. Non Peo Neo Avg Comp Actually Paid Amt
REGENXBIO Inc. (RGNX) reported Non Peo Neo Avg Comp Actually Paid Amt of $3.86 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-14.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-14
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $3.86M DEF 14A · filed 2026-04-14 |
| 2024-12-31 | $819.07K DEF 14A · filed 2026-04-14 |
| 2023-12-31 | $2.05M DEF 14A · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |